13F Pro13F Pro

SEC Form 4 reporting owner

Thompson Peter A.

Thompson Peter A. has filed 29 Form 4 transactions reported between December 17, 2025 and November 2, 2026, as Director of Aspen Neuroscience, Inc., Director of Sionna Therapeutics, Inc., a reporting owner of ARS Pharmaceuticals, Inc., Director of Corvus Pharmaceuticals, Inc. and a reporting owner of Edgewise Therapeutics, Inc..

Name as filed: Thompson Peter A.

Follow Thompson Peter A. and get an alert on every new Form 4

Thompson Peter A. holds 3.6M shares of ASPE, worth $44.5M.

As of their Nov 2, 2026 Form 4 (filed Nov 4, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $12.39

Thompson Peter A. holds 2.5M shares of SION, worth $7.3M, 5.46% of the company.

As of their Jul 7, 2026 Form 4 (filed Jul 9, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $2.97 · 45.2M shares outstanding on Oct 30, 2026

Open-market buys, 24 mo
$15.0M
1 lines
Open-market sales, 24 mo
$50.9M
17 lines
Companies
5
with Form 4 filings
Latest transaction
Nov 2, 2026
transaction date

Roles and reported holdings

  • ASPEAspen Neuroscience, Inc.
    Nov 2, 2026

    Director

    See footnotes3,589,132 sh

    As of Nov 2, 2026 · Form 4

    24 months: $15.0M bought

  • SIONSionna Therapeutics, Inc.
    Dec 17, 2025 – Jul 7, 2026

    Director

    See footnotes2,469,959 sh

    Also reports 17,340 Non-Qualified Stock Option (right to buy), not counted as shares.

    As of Jul 7, 2026 · Form 4

    Shares held, direct and indirect, SION, after each Form 4
    2.5M2.5M2.6MJun 30, 2026: 2.6M shares (Form 4)Jul 7, 2026: 2.5M shares (Form 4)Jun 30, 2026Jul 7, 2026
    FilingShares afterChange
    Jul 7, 20262.5M−86K
    Jun 30, 20262.6M—

    24 months: $50.9M sold

  • SPRYARS Pharmaceuticals, Inc.
    Jun 24, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • CRVSCorvus Pharmaceuticals, Inc.
    Jan 28, 2026 – Jun 11, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • EWTXEdgewise Therapeutics, Inc.
    Jun 5, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

How their buys did since

1 open-market purchase against today’s price: -17.4% on average.

DatePaidReturn
Nov 2, 2026ASPE$15.00-17.4%now $12.39

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 29 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Nov 2, 2026ASPEDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC1,000,000$15.0M@ $15.00Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect507,119—Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect625,743—Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect616,984—Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect642,745—Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect196,541—Form 4
Jul 7, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC85,918$3.9M@ $44.86Form 4
Jun 30, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC115,844$5.3M@ $45.50Form 4
Jun 24, 2026SPRYGrant or awardCode A · direct30,000—Form 4
Jun 17, 2026SIONDirectorGrant or awardCode A · direct17,340—Form 4
Jun 11, 2026CRVSGrant or awardCode A · direct15,000—Form 4
Jun 5, 2026EWTXGrant or awardCode A · direct16,377—Form 4
May 27, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC101$4K@ $44.49Form 4
May 11, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC184,639$8.5M@ $46.22Form 4
May 8, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC59,767$2.7M@ $44.58Form 4
May 7, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC48,546$2.2M@ $44.61Form 4
Apr 18, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC2,948$131K@ $44.52Form 4
Apr 17, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC52,397$2.3M@ $44.68Form 4
Apr 16, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC226,906$10.3M@ $45.34Form 4
Apr 15, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC235,863$10.5M@ $44.64Form 4
Apr 14, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC47,814$2.1M@ $44.51Form 4
Feb 3, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC29,063$1.3M@ $44.58Form 4
Feb 2, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC1,890$84K@ $44.57Form 4
Jan 28, 2026CRVSDirectorOption exerciseCode M · direct15,000$146K@ $9.70Form 4
Jan 28, 2026CRVSDirectorOption exerciseCode M · direct30,000$450K@ $15.00Form 4
Dec 24, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC33,356$1.5M@ $44.55Form 4
Dec 19, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC875$39K@ $44.49Form 4
Dec 18, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC100$4K@ $44.49Form 4
Dec 17, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by ORBIMED ADVISORS LLC900$40K@ $44.50Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.